Last reviewed · How we verify
PDC*lung01
At a glance
| Generic name | PDC*lung01 |
|---|---|
| Sponsor | PDC*line Pharma SAS |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PDC*lung01 CI brief — competitive landscape report
- PDC*lung01 updates RSS · CI watch RSS
- PDC*line Pharma SAS portfolio CI